Business
Voyageur Recaps Significant 2024 Achievements and Unveils Plans for Transformational 2025, Including Market Launch for Barium Suite of Products and Advancement of Iodine Suite
(TheNewswire) LOI with Multinational Contrast Media Company Voyageur Introd...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Recaps Significant 2024 Achievements and Unveils Plans for Transformational 2025, Including Market Launch for Barium Suite of Products and Advancement of Iodine Suite\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n LOI with Multinational Contrast\nMedia Company\n \n\n\n\n\n\n Voyageur Introduced Five New Health\nCanada Licensed Barium Contrast Products\n \n\n\n\n\n\n Securing 1st Sales Contract\n \n\n\n\n\n\n Calgary, Alberta, Canada –\n \n\n TheNewswire -\n \n\n January 1\n \n\n 5\n \n\n , 2025 - Voyageur Pharmaceuticals Ltd.\n(TSX.V:VM) (OTC Pink:VYYRF) (\"\n \n\n Voyageur\n \n\n \" or the\n\"\n \n\n Company\n \n\n \"), a company vertically integrating the medical imaging\nindustry, is pleased to recap a series of achievements and upcoming\ninitiatives that highlight Voyageur's progress and innovations.\n \n\n\n\n 2024 was a pivotal year for Voyageur with multiple\nachievements:\n \n\n\n\n 2024 Significant Highlights\n \n\n\n\n\n\n LOI with Multinational Contrast Media\nCompany:\n \n\n\n\n\n\n\n\n\n\n\n December 20,\n2024\n \n\n\n -\n \n\n The Company announced that it  entered into a Letter of\nIntent agreement with a large multinational pharmaceutical company\naiming to gain efficiencies in production of contrast media\nproducts.\n \n\n Voyageur believes that partnering with\na large multinational pharmaceutical company to expand entry into\nother contrast media markets will benefit all areas of Voyageur’s\nbusiness. Both parties are working toward a definitive agreement in\nearly 2025.\n \n\n\n\n\n\n\n\n\n\n Strengthened Leadership\nTeam:\n \n\n\n\n\n\n\n\n\n\n\n September 24,\n2024\n \n\n\n - Voyageur strengthened its global\nleadership with the appointment of\n \n\n Dr. Ibrahim Hashmi\n \n\n ,\nas Vice President of Business Development. Dr Hashmi has 25 years of\ncommercial management experience in the radiology contrast drug market\nand adds a wealth of strategic expertise to drive the Company's growth\ntrajectory.\n \n\n\n\n\n\n\n\n\n\n\n\n\n September 17,\n2024\n \n\n\n - Voyageur proudly welcomed\n \n\n Dr. Iryna Saranchova, PhD,\nMD\n \n\n , as the Company’s Chief Scientific Officer,\nunderscoring its commitment to pioneering research and advancing\nhealthcare through cutting-edge science. Dr. Saranchova is leading our\ndrug development progr...